{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:58:28Z","timestamp":1784793508251,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.04.064","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T01:32:45Z","timestamp":1620869565000},"page":"3388-3396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14\u00a0years in Mexico"],"prefix":"10.1016","volume":"39","author":[{"given":"Jose Luis","family":"Arredondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Maria","family":"Villagomez Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Concepcion Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7866-2448","authenticated-orcid":false,"given":"Myew-Ling","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Zocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-9814","authenticated-orcid":false,"given":"Claire","family":"Vigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Mascare\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.064_b0005","unstructured":"World Health Organization., Dengue and severe dengue. WHO factsheet. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue. 2019."},{"issue":"2","key":"10.1016\/j.vaccine.2021.04.064_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.glohj.2019.06.002","article-title":"Dengue epidemiology","volume":"3","author":"Jing","year":"2019","journal-title":"Glob Health J"},{"issue":"9951","key":"10.1016\/j.vaccine.2021.04.064_b0015","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2021.04.064_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"9853","key":"10.1016\/j.vaccine.2021.04.064_b0025","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2021.04.064_b0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.04.064_b0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.vaccine.2021.04.064_b0040","first-page":"457","article-title":"Dengue vaccine: WHO position paper \u2013 September 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"issue":"19","key":"10.1016\/j.vaccine.2021.04.064_b0045","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2021.04.064_b0050","doi-asserted-by":"crossref","unstructured":"al, J.B.e., Safety of Co-Administration Versus Separate Administration of the Same Vaccines in Children: A Systematic Literature Review. Vaccines, 2020(8): p. 12.","DOI":"10.3390\/vaccines8010012"},{"issue":"7","key":"10.1016\/j.vaccine.2021.04.064_b0055","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2021.04.064_b0060","unstructured":"Human Papillomavirus vaccine [Types 16, R., adjuvanted, adsorbed). Cervarix., Summary of Product Characteristics. GlaxoSmithKline Biologicals s.a. Belgium. [Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cervarix-epar-product-information_en.pdf]."},{"key":"10.1016\/j.vaccine.2021.04.064_b0065","unstructured":"Dengvaxia, p.a.s.f.s.f.i.i.p.-f.s.d.t.v.l., attenuated)., Summary of Product Characteristics. Sanofi Pasteur, France. [Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dengvaxia-epar-product-information_en.pdf]."},{"issue":"5","key":"10.1016\/j.vaccine.2021.04.064_b0070","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2021.04.064_b0075","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/j.vaccine.2021.04.064_b0080","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316 year olds: a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2021.04.064_b0085","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2021.04.064_b0090","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9\u201314 years versus a 3-dose regimen in women Aged 15\u201325 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2021.04.064_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2021.04.064_b0100","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/EDBK_249695","article-title":"HPV vaccination in Latin America: Global challenges and feasible solutions","volume":"39","author":"Nogueira-Rodrigues","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.vaccine.2021.04.064_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection","volume":"26","author":"Bonaparte","year":"2019","journal-title":"J Travel Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.04.064_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114918","article-title":"Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening","volume":"96","author":"Bonaparte","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.064_b0115","article-title":"Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials","author":"DiazGranados","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.04.064_b0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:49Z","timestamp":1759402609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":24,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21005466"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14\u00a0years in Mexico","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}